Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Unknown 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Carcinoma, Basal Cell 2Breast Diseases 2Basal Cell Nevus Syndrome 2Thrombocythemia, Essential 1Polycythemia Vera 1Hypogonadism 1Glioma 1Gastric Adenocarcinoma 1Fatigue Syndrome, Chronic 1Eunuchism 1Colorectal Neoplasms 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × Drug Evaluation × Clear all
NCT02538471 2019-12-09

LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer

Weill Medical College of Cornell University

Phase 2 Terminated
3 enrolled 11 charts
Breast

Breast Neoplasms

NCT04088110 2019-09-12

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Fuzhou General Hospital

Phase 2 Unknown
77 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

Peking Union Medical College Hospital

Phase 2 Unknown
250 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡